CN106589088B - Polypeptide with antibacterial and anti-inflammatory activity and application thereof - Google Patents
Polypeptide with antibacterial and anti-inflammatory activity and application thereof Download PDFInfo
- Publication number
- CN106589088B CN106589088B CN201611040907.6A CN201611040907A CN106589088B CN 106589088 B CN106589088 B CN 106589088B CN 201611040907 A CN201611040907 A CN 201611040907A CN 106589088 B CN106589088 B CN 106589088B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- antibacterial
- acnes
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 38
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 36
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 23
- 230000003110 anti-inflammatory effect Effects 0.000 title description 11
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 25
- 206010000496 acne Diseases 0.000 claims abstract description 18
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 17
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 11
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 230000000813 microbial effect Effects 0.000 claims abstract description 5
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000000645 desinfectant Substances 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 208000015181 infectious disease Diseases 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 16
- AJHCSUXXECOXOY-NSHDSACASA-N Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-NSHDSACASA-N 0.000 claims description 13
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 claims description 13
- 108010084389 glycyltryptophan Proteins 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 206010040882 skin lesion Diseases 0.000 claims description 4
- 231100000444 skin lesion Toxicity 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 229960002227 clindamycin Drugs 0.000 abstract description 15
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 abstract description 15
- 230000003115 biocidal effect Effects 0.000 abstract description 12
- 239000003242 anti bacterial agent Substances 0.000 abstract description 10
- 230000002147 killing effect Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 241000233866 Fungi Species 0.000 abstract description 4
- 241000192125 Firmicutes Species 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 241000257465 Echinoidea Species 0.000 abstract description 2
- 206010017533 Fungal infection Diseases 0.000 abstract description 2
- 208000031888 Mycoses Diseases 0.000 abstract description 2
- 241000235342 Saccharomycetes Species 0.000 abstract description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract description 2
- 150000001413 amino acids Chemical group 0.000 abstract description 2
- 239000012634 fragment Substances 0.000 abstract description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 210000001616 monocyte Anatomy 0.000 description 10
- 238000013461 design Methods 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 description 7
- 239000002260 anti-inflammatory agent Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 6
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 3
- LZLREEUGSYITMX-JQWIXIFHSA-N Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-JQWIXIFHSA-N 0.000 description 3
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 241000751182 Staphylococcus epidermidis ATCC 12228 Species 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 241000243818 Annelida Species 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000142520 Myxine Species 0.000 description 1
- 241000243827 Nereis Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- JIDVGUQUQSOHOL-UHFFFAOYSA-N myxin Chemical compound C1=CC=C2[N+]([O-])=C3C(OC)=CC=CC3=[N+]([O-])C2=C1O JIDVGUQUQSOHOL-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a polypeptide, the molecular weight is 3321.6Da, and the amino acid sequence is shown in SEQ ID NO. 1. The present invention also provides six kinds of derivatives of the polypeptide. The polypeptide and the derivatives thereof provided by the invention have high-efficiency broad-spectrum antibacterial effects such as gram-positive bacteria and gram-negative bacteria (particularly have good killing effect on anaerobic propionibacterium acnes resisting clindamycin), fungi and saccharomycetes, and high activity (the concentration for killing propionibacterium acnes in vitro can be only 0.125 mg/L). Can be used for preparing products for controlling microbial and fungal infection and resisting inflammation, wherein the products comprise external disinfectants, antibacterial agents, wound protection or infection prevention dressings, acne treatment medicines, skin care products, cosmetics and the like. The polypeptide is designed and synthesized based on the fragment containing the tryptophan bromide of the sea urchin, and has stronger effects of inhibiting or killing bacteria and resisting inflammation and better stability. Can be used as antibiotic substitute.
Description
Technical Field
The invention belongs to the technical field of biology, and relates to a polypeptide with antibacterial and anti-inflammatory activities, and application thereof in preparing a medicament containing the polypeptide and an external product such as a dressing, a skin care product or a cosmetic.
Background
Antimicrobial peptides (antibiotics) are a class of small molecule defense polypeptides synthesized by organisms and are important members of the animal's innate immune system. In 1972, Boman et al, a swedish scientist, first discovered antibacterial peptides in fruit ropes and their immune function, and then discovered and isolated thousands of polypeptides with antibacterial activity from bacteria, fungi, higher plants, invertebrates, vertebrates, and even humans in sequence by many researchers.
the antibacterial mechanism of antibacterial peptide is that the antibacterial peptide approaches cell membrane through cation, then the antibacterial peptide is inserted into biological membrane through hydrophobic amino acid, if the concentration is proper or higher, transmembrane channel is formed or membrane is broken, intracellular substance is leaked and transmembrane potential is disrupted, thus bacterial cell lysis death is caused, if the concentration of the antibacterial peptide is lower, pathogen is not killed effectively, part of the antibacterial peptide enters into cell and combines with intracellular polyanion (such as DNA and protein) to inhibit microbial reproduction, and most probably, the antibacterial peptide has broad spectrum antibacterial action, has the effect of inhibiting gram-positive bacteria, gram-negative bacteria and fungi, and can also inhibit protozoan, antivirus and kill tumor cells in animal bodies, thus the antibiotic substitute antibiotic becomes a new generation of relatively safe antibacterial drug, the antibacterial and anti-inflammatory activity of cation can be summarized as 1, the antibacterial and anti-inflammatory activity of antibacterial peptide can be induced by the effect of (1) and the effect of the antibiotic peptide and the antibiotic effect of inhibiting the antibiotic effect of bacteria, such as the antibiotic effect of antibiotic, anti-inflammatory and anti-inflammatory activity of antibiotic peptide (such as alpha-TNF) can be generated by the antibiotic effect of antibiotic, anti-inflammatory peptide and anti-inflammatory peptide (TNF-.
For many years, the structural effect research make internal disorder or usurp of antibacterial peptide has been one of the hot spots of the antibacterial peptide research make internal disorder or usurp. People adjust the structure of natural antibacterial peptide to achieve the purposes of improving activity and reducing toxicity. However, the results of the design are still not satisfactory. In recent years, with the research and development of marine organisms, antibacterial peptides containing a large amount of brominated tryptophan have been isolated, such as sterelin D isolated from marine tunicate (sterula clavata), cathelicidins isolated from pacific eel (Myxine globinosa), and hedatin extracted from marine annelid (Nereis diversiocolor). At present, the biological effect on the brominated tryptophan is still unclear, but the existence of the bromination modification can convert the side chain of the tryptophan into a substrate with weaker affinity to endogenous proteolytic enzyme, so that the antibacterial peptide is protected from being hydrolyzed by the protein, and the antibacterial activity of the antibacterial peptide is enhanced.
Disclosure of Invention
One object of the present invention is to provide a polypeptide (GW28-Br), the amino acid sequence of which is shown in SEQ ID NO. 1: GlyTrp (Br) PheLysLysThrPheHisLysValSerHisALAValLysGlyIleHisAGlyGlnGlyCysSerAlLeuGlyPhe, molecular weight 3321.6 Da.
Another object of the present invention is to provide six derivatives of the polypeptide GW28-Br, the amino acid sequences of which are respectively shown as follows:
SEQ ID NO.2:GlyTrp(Br)PheLysLysThrPheHisLysValSerHisAlaValLysSerGlyIleHisAla；
SEQ ID NO.3:SerTrp(Br)PheSerArgThrValHisAsnValGlyAsnAlaValArgLysGlyIleHisAlaGlyGlnGlyValCysSerGlyLeuGlyLeu；
SEQ ID NO.4：
GlyTrp(Br)Trp(Br)ArgArgThrValAspLysValArgAsnAlaGlyArgLysValAlaGlyPheAlaSerLysAlaCysGlyAlaLeuGlyHis；
SEQ ID NO.5：GlyTrp(Br)Trp(Br)ArgArgThrValAspLysValArgAsnAlaGlyArgLysValAla；
SEQ ID NO.6：
Trp(Br)GlyHisLysLeuArgSerSerTrp(Br)AsnLysValLysHisAlaValLysLysGlyAlaGlyTyrAlaSerGlyAlaCysArgValLeuGlyHis；
SEQ ID NO.7：Trp(Br)GlyHisLysLeuArgSerSerTrp(Br)AsnLysValLysHisAlaValLysLys。
other further derivatives are those in which one amino acid residue in the above polypeptide (SEQ ID NO.1) or polypeptide derivatives (SEQ ID NO.2-7) is substituted, or one amino acid residue is deleted at one end of the polypeptide sequence, or two amino acid residues are deleted at one end of the polypeptide sequence.
Another objective of the invention is to provide application of the polypeptide in preparing products for controlling microbial and bacterial infections and fungal infections and resisting inflammation, wherein the products comprise external disinfectants, antibacterial agents, wound protection or infection prevention dressings, acne treatment medicines, skin care products, cosmetics and the like.
The polypeptide is designed and synthesized based on the fragment containing the brominated tryptophan of the sea urchin, is a novel polypeptide, and has stronger effects of inhibiting or killing bacteria and resisting inflammation and better stability.
The polypeptide provided by the invention has high-efficiency broad-spectrum antibacterial action such as gram-positive bacteria and gram-negative bacteria (particularly has a good killing effect on anaerobic propionibacterium acnes resisting clindamycin), fungi and saccharomycetes, and high activity (the concentration for killing propionibacterium acnes in vitro can be only 0.125 mg/L). Can be used as antibiotic substitute.
Drawings
FIG. 1 shows the cytotoxicity test of GW28-Br on human HaCaT cells and monocytes. The blue square is the cell activity value of the HaCaT cell treated by GW28-Br with different concentrations for 24 hours, and the black triangle is the cell activity value of the monocyte treated by GW28-Br with different concentrations for 24 hours. Data are the average of three independent experiments.
FIG. 2A shows the inhibitory effect of GW28-Br on IL-12p40 secreted by human peripheral blood mononuclear cells. GW28-Br significantly inhibited IL-12p40 expression induced by acnes in a dose-dependent manner IC50 ═ 23.19mg/l.
FIG. 2B is a graph showing the inhibitory effect of GW28-Br on IL-12p40 secreted by human keratinocyte HaCat cells. GW28-Br significantly inhibited acnes from inducing expression of IL-12p40 in a dose-dependent form IC 50-8.31 mg/L. The data in the figure are mean ± sd of three independent experiments.
FIG. 3A is a graph of the inhibitory effect of GW28-Br and clindamycin on the secretion of TLR2 in human peripheral blood mononuclear cells induced by P.acnes. The data in the figure are mean ± sd of three independent experiments.
FIG. 3B is a graph of the inhibitory effect of GW28-Br and clindamycin on IL-10 secretion in human peripheral blood mononuclear cells induced by P.acnes.
FIG. 3C is a graph of the inhibitory effect of GW28-Br and clindamycin on IL-6 secretion in human peripheral blood mononuclear cells induced by P.acnes.
FIG. 3D is a graph of the inhibitory effect of GW28-Br and clindamycin on IL-1 β secretion in human peripheral blood mononuclear cells induced by acne bacilli.
FIG. 3E is a graph of the inhibitory effect of GW28-Br and clindamycin on TNF- α secretion in human peripheral blood mononuclear cells induced by P.acnes.
FIG. 4 shows the expression changes of MMP2, TNF- α and TLR-2 in ear skin (SP immunohistochemistry,. times.20) of rats with acne model after 2 weeks of external application of physiological saline, GW28-Br and clindamycin solutions, respectively.
Detailed Description
The present invention will be further described with reference to the following examples. The examples are intended to illustrate the invention, but not to limit it in any way.
Example 1: polypeptide 1(GW28-Br)
A polypeptide 1(GW28-Br), is a small molecule derived from antibacterial peptide Centrocin, is composed of 30 amino acid residues and is modified by bromination, the molecular weight is 3321.6 Da.GW28-Br is amphiphilic with a polar surface and a non-polar surface, and the nucleotide sequence of the polypeptide 1(GW28-Br) is shown in SEQ ID NO. 1:
GlyTrp(Br)PheLysLysThrPheHisLysValSerHisAlaValLysSerGlyIleHisAlaGlyGlnArgGlyCysSerAlaLeuGlyPhe。
example 2: polypeptide derivatives
The amino acid sequences of the six derivatives of the polypeptide 1(GW28-Br) are respectively shown as follows:
SEQ ID NO.2:GlyTrp(Br)PheLysLysThrPheHisLysValSerHisAlaValLysSerGlyIleHisAla；
SEQ ID NO.3:SerTrp(Br)PheSerArgThrValHisAsnValGlyAsnAlaValArgLysGlyIleHisAlaGlyGlnGlyValCysSerGlyLeuGlyLeu；
SEQ ID NO.4：
GlyTrp(Br)Trp(Br)ArgArgThrValAspLysValArgAsnAlaGlyArgLysValAlaGlyPheAlaSerLysAlaCysGlyAlaLeuGlyHis；
SEQ ID NO.5：GlyTrp(Br)Trp(Br)ArgArgThrValAspLysValArgAsnAlaGlyArgLysValAla；
SEQ ID NO.6：
Trp(Br)GlyHisLysLeuArgSerSerTrp(Br)AsnLysValLysHisAlaValLysLysGlyAlaGlyTyrAlaSerGlyAlaCysArgValLeuGlyHis；
SEQ ID NO.7：Trp(Br)GlyHisLysLeuArgSerSerTrp(Br)AsnLysValLysHisAlaValLysLys。
the further derivatives are derivatives obtained by substituting one amino acid residue in the polypeptide 1(SEQ ID NO.1) or polypeptide derivatives (SEQ ID NO.2-7), or deleting one amino acid residue at one end of the polypeptide sequence, or deleting two amino acid residues at one end of the polypeptide sequence.
Example 3: evaluation of in vitro antibacterial activity of GW28-Br
Isolated corynebacterium acnes were collected clinically from lesions of 15 acne patients, and MIC values (minimum inhibitory concentration) of GW28-Br and clindamycin against the clinically isolated strains and ATCC strains were measured by the microbench broth method. As shown in Table 1, GW28-Br showed significant inhibitory effect on clinically isolated Corynebacterium acnes, including 6 clindamycin-resistant strains. The mean MIC value of GW28-Br was 11.8mg/L, which is significantly lower than the MIC value of 31.2mg/L (P <0.05) for clindamycin against 9 clinical strains of Corynebacterium acnes. GW28-Br also inhibited Staphylococcus aureus ATCC 25913(MIC value 32mg/L) and Staphylococcus epidermidis ATCC12228(MIC value 16mg/L) which are common in acne lesions, whereas clindamycin only inhibited Staphylococcus epidermidis ATCC12228(MIC value 64 mg/L).
TABLE 1 MIC values (mg/L) of the polypeptides GW28-Br and clindamycin for Corynebacterium acnes. 1-15 clinically isolated corynebacterium acnes strains
Example 3: cytotoxicity detection of antibacterial peptide GW28-Br
Propionibacterium acnes acts primarily on human keratinocytes and induces expression of inflammatory cells. Therefore we used human keratinocytes HaCaT cells and monocytes to evaluate GW28-Br cytotoxicity. The experimental result shows that GW28-Br has no obvious influence on the cell activity of HaCaT cells and monocytes (the influence on the cell activity of GW28-Br at a concentration within 200mg/L is less than 7.5%, FIG. 1). Therefore, GW28-Br at a concentration within 200mg/L has no obvious cytotoxicity to monocytes and keratinocytes, and the concentration is far higher than the inhibitory concentration of GW28-Br to clinical corynebacterium acnes.
Example 4: effect of GW28-Br on inflammatory cytokine expression
it has been shown that Propionibacterium acnes induced IL-12 expression in HaCaT cells or monocytes after 24 hours of co-treatment of HaCaT cells and monocytes with Propionibacterium acnes using GW28-Br at a concentration of between 1mg/L and 100mg/L, the amount of IL-12p40 secretion induced by Propionibacterium acnes was significantly reduced (FIGS. 2A, 2B), whereas treatment of HaCaT cells and monocytes with GW28-Br alone for 24 hours did not induce IL-12p40 secretion, Propionibacterium acnes caused an inflammatory response to acne by activating TLR2, resulting in the release of inflammatory cytokines of the NF- κ B signaling pathway such as IL-6, IL-1 β, IL-10 and TNF- α. therefore, we used the Elispot method to examine whether GW28-Br affected Propionibacterium acnes-induced expression of TLR2 in monocytes after 24 hours of human peripheral blood CD 4+ monocyte cells cultured in isolation, inoculated with TNF 6323 for 24 hours, increased amounts twice as compared to the amount of IL-12 p-Br in HaCaT cells after 24 hours, but showed significant decrease in the expression of TNF-19-Br in the ELISA 3-2-Br-2-g and the expression of TNF-Br-2-co-2-Br-2-and the anti-TNF-beta-TNF-expressing IL-Br-TNF-expressing TNF-beta-expressing IL-TNF-expressing IL-beta-Br, and the TNF-beta-TNF-beta-TNF-expressing TNF-beta-expressing TNF-beta-TNF-beta-TNF-beta.
Example 5: research on effect of antibacterial peptide GW28-Br on rat acne model
the skin lesions of rats in groups A are initially thickened and gradually increased after being injected for 24h, acne-like skin lesions such as pimples and pustules appear on day 5, reddish red and hard, B, C the skin lesions of rats in groups A are basically subsided after being injected for 2 weeks by clindamycin 0.1% solution and GW 28-Br0.05% solution, the thickness is thinned and the color is normal, the skin tissues of rats in groups right injected for 5 days are taken, the left ear skin tissues of rats which are not injected with corynebacterium acnes are observed to be thinner by HE staining, the skin tissues of rats in groups A are visible, the junction between dermis and dermis, the skin tissues of groups A are clearly over-thickened and become normal, the skin tissues of rats in groups are taken, the skin tissues of rats in groups right injected for right, the rats are observed to be thinner after being injected with the clindamycin 0.1% solution and the GW 28-Br0.05% solution, the tissues of the rats are remarkably soaked in the MMP-2, the areas of the skin tissues of the rat skin tissues of the rat are remarkably reduced after being injected for 2 weeks, the inflammatory tissues of the rat, the rat skin tissues of the rat are remarkably reduced by MMP-9-Br-9 MMP-Br-9-MMP-7-MMP-2, and the rat-TFA junction is observed after being remarkably reduced after being injected for the rat skin tissues of the rat.
Example 6 of implementation: GW28-Br for external use for acne patients
Based on the anti-inflammatory and antibacterial effects of GW28-Br, with the informed consent of acne patients, a 0.05% solution of GW28-Br was externally applied to the face of moderate acne patients for 1 week to observe the curative effect, and the facial VISA detector before and after use was used to take pictures and count the number of acne papules. After the right side face of the patient uses the GW28-Br solution for 1 week, the patient has no complaints of irritability such as pain, pruritus and the like, the acne skin damage is obviously improved, the number of acne papules and the inflammation score are obviously reduced, and the untreated left side face has no obvious improvement.
<110> Zhejiang university
<120> polypeptide with antibacterial and anti-inflammatory activity and application thereof
<160>7
<210>1
<211>30
<212>PRT
<213> Artificial sequence
<220>
<223> design according to amino acid sequence for antibacterial and/or anti-inflammatory agent
<400>1
GlyTrp(Br)PheLysLysThrPheHisLysValSerHisAlaValLysSerGlyIleHisAlaGlyGlnArgGlyCysSerAlaLeuGlyPhe
1 5 10 15 2025 30
<210>2
<211>20
<212>PRT
<213> Artificial sequence
<220>
<223> design according to amino acid sequence for antibacterial and/or anti-inflammatory agent
<400>2
GlyTrp(Br)PheLysLysThrPheHisLysValSerHisAlaValLysSerGlyIleHisAla
1 5 10 15 20
<210>3
<211>30
<212>PRT
<213> Artificial sequence
<220>
<223> design according to amino acid sequence for antibacterial and/or anti-inflammatory agent
<400>3
SerTrp(Br)PheSerArgThrValHisAsnValGlyAsnAlaValArgLysGlyIleHisAlaGlyGlnGlyValCysSerGlyLeuGlyLeu
1 5 10 15 2025 30
<210>4
<211>30
<212>PRT
<213> Artificial sequence
<220>
<223> design according to amino acid sequence for antibacterial and/or anti-inflammatory agent
<400>4
GlyTrp(Br)Trp(Br)ArgArgThrValAspLysValArgAsnAlaGlyArgLysValAlaGlyPheAlaSerLysAlaCysGlyAlaLeuGlyHis
1 5 1015 2025 30
<210>5
<211>18
<212>PRT
<213> Artificial sequence
<220>
<223> design according to amino acid sequence for antibacterial and/or anti-inflammatory agent
<400>5
GlyTrp(Br)Trp(Br)ArgArgThrValAspLysValArgAsnAlaGlyArgLysValAla
1 5 10 15
<210>6
<211>32
<212>PRT
<213> Artificial sequence
<220>
<223> design according to amino acid sequence for antibacterial and/or anti-inflammatory agent
<400>6
Trp(Br)GlyHisLysLeuArgSerSerTrp(Br)AsnLysValLysHisAlaValLysLysGlyAlaGlyTyrAlaSerGlyAlaCysArgValLeuGlyHis
1 5 10 15 2025 30
<210>7
<211>18
<212>PRT
<213> Artificial sequence
<220>
<223> design according to amino acid sequence for antibacterial and/or anti-inflammatory agent
<400>7
Trp(Br)GlyHisLysLeuArgSerSerTrp(Br)AsnLysValLysHisAlaValLysLys
1 5 10 15
Claims (2)
1. The application of a polypeptide GW28-Br in inhibiting corynebacterium acnes is characterized in that the molecular weight of the polypeptide is 3321.6Da, and the amino acid sequence is shown as SEQ ID No. 1:
GlyTrp(Br)PheLysLysThrPheHisLysValSerHisAlaValLysSerGlyIleHisAlaGlyGlnArgGlyCysSerAlaLeuGlyPhe；
the polypeptide GW28-Br is amphiphilic water-based α -helical antibacterial peptide with a polar surface and a non-polar surface, the minimum inhibitory concentration of the polypeptide GW28-Br for inhibiting the corynebacterium acnes is 0.12mg/L, and the corynebacterium acnes is separated from skin lesions of acne patients.
2. The use of the polypeptide GW28-Br of claim 1 in the preparation of a product for the control of microbial bacteria, wherein said product comprises topical disinfectants, antimicrobials, wound protection or infection prevention dressings, acne treatment medications, skin care products, cosmetics; the microbial bacteria are propionibacterium acnes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611040907.6A CN106589088B (en) | 2016-11-21 | 2016-11-21 | Polypeptide with antibacterial and anti-inflammatory activity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611040907.6A CN106589088B (en) | 2016-11-21 | 2016-11-21 | Polypeptide with antibacterial and anti-inflammatory activity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106589088A CN106589088A (en) | 2017-04-26 |
| CN106589088B true CN106589088B (en) | 2020-05-19 |
Family
ID=58592843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611040907.6A Active CN106589088B (en) | 2016-11-21 | 2016-11-21 | Polypeptide with antibacterial and anti-inflammatory activity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106589088B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201620963D0 (en) * | 2016-12-09 | 2017-01-25 | Univ I Troms� - Norges Arktiske Univ | Antimicrobial peptides |
| CN107496904B (en) * | 2017-09-21 | 2020-03-17 | 中南大学 | Application of polypeptide Lycosin-I in preparation of anti-inflammatory and anti-toxoplasma gondii drugs |
| CN107652362B (en) * | 2017-09-25 | 2020-06-05 | 中国药科大学 | Antibacterial polypeptide EC1-17KV and application thereof |
| CN109266655B (en) * | 2018-09-06 | 2021-11-09 | 浙江大学 | Antibacterial peptide and prokaryotic expression method and application thereof |
| CN113461779B (en) * | 2021-06-04 | 2023-04-25 | 温州肯恩大学 | Anti-inflammatory polypeptide and synthetic method thereof |
| CN114209808B (en) * | 2021-12-24 | 2023-08-18 | 成都佩德生物医药有限公司 | Application of polypeptide RK12 in preparation of medicines for treating acne |
| CN114209809B (en) * | 2021-12-24 | 2023-09-05 | 成都佩德生物医药有限公司 | Combined pharmaceutical composition for resisting propionibacterium acnes and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008002153A2 (en) * | 2006-06-30 | 2008-01-03 | University of Tromsø | Novel polypeptides |
-
2016
- 2016-11-21 CN CN201611040907.6A patent/CN106589088B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008002153A2 (en) * | 2006-06-30 | 2008-01-03 | University of Tromsø | Novel polypeptides |
Non-Patent Citations (1)
| Title |
|---|
| Centrocins: Isolation and characterization of novel dimeric antimicrobial peptides from the green sea urchin, Strongylocentrotus droebachiensis;Chun Li等;《Developmental and Comparative Immunology》;20101231;第34卷;第965页图6B，左栏第3.5节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106589088A (en) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106589088B (en) | Polypeptide with antibacterial and anti-inflammatory activity and application thereof | |
| AlMatar et al. | Antimicrobial peptides as an alternative to anti-tuberculosis drugs | |
| Conlon | The contribution of skin antimicrobial peptides to the system of innate immunity in anurans | |
| US7381704B2 (en) | Methods for use of short bioactive peptides | |
| Otvos Jr et al. | Therapeutic utility of antibacterial peptides in wound healing | |
| US11116810B2 (en) | Methods for treatment of skin and skin appendages with a linseed extract as an active agent activating the synthesis of antimicrobial peptides | |
| KR20180056226A (en) | Antimicrobial Peptide Analogues Derived From The Abalone, Haliotis Discus, And Antimicrobial Pharmaceutical Composition Containing The Same | |
| Jeong et al. | Antibiotic and synergistic effect of Leu–Lys rich peptide against antibiotic resistant microorganisms isolated from patients with cholelithiasis | |
| KR20150042447A (en) | Antibiotic peptide analogues with high activities against multidrug resistant bacteria and fungi and anti-inflammatory activities designed from Protaetiamycine, and their uses | |
| Besednova et al. | Cephalopods: The potential for their use in medicine | |
| Ferreira et al. | Evaluation of antimicrobial, cytotoxic, and hemolytic activities from venom of the spider Lasiodora sp. | |
| DK2961481T3 (en) | TOPICAL ANTIMICROBIAL DERMATOLOGICAL COMPOSITION | |
| Ganesan et al. | Marine invertebrates’ proteins: A recent update on functional property | |
| CN106668850A (en) | Natural bactericides/antibacterial agents | |
| DE102012203547A1 (en) | Antimicrobial peptides | |
| Luo et al. | Novel lactotransferrin-derived synthetic peptides suppress cariogenic bacteria in vitro and arrest dental caries in vivo: [Novel lactotransferrin-derived anticaries peptides] | |
| AU2016221298B2 (en) | Antimicrobial peptides | |
| Cirioni et al. | IB-367 pre-treatment improves the in vivo efficacy of teicoplanin and daptomycin in an animal model of wounds infected with meticillin-resistant Staphylococcus aureus | |
| JP6162341B2 (en) | Antifungal composition containing antifungal peptide and terpene alcohol | |
| US20210244785A1 (en) | Compositions and methods for the antiseptic treatment of biofilms on mammalian tissue | |
| US20050209157A1 (en) | Short bioactive peptides and methods for their use | |
| KR101430084B1 (en) | Novel antibiotic peptide against Propionibacterium acnes and use therof | |
| KR101638664B1 (en) | Pharmaceutical composition for preventing or treating infectious diseases of skin comprising 5-Aminolevulinic acid | |
| KR101905016B1 (en) | Antimicrobial Peptide Derived From The Mytilus coruscus And Its Use | |
| KR102162474B1 (en) | Cosmetics with antimicrobial peptide as antiseptic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |